Author:
Kassogue Yaya,Quachouh Meryem,Dehbi Hind,Quessar Asma,Benchekroun Said,Nadifi Sellama
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference36 articles.
1. Deininger MWN, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia Review article. Blood. 2000;96:3343–56.
2. Buchdunger E, Zimmermann J, Mett H, Lydon NB, Meyer T, Muller M, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996;56:100–4.
3. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15618470 .
4. O’Brien SG, Guilhot F, Larson R a, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12637609 .
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11287972 .
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献